GSK’s Myeloma Drug Gets AdComm Backing, But Limitations Remain Clear

Likely To Be First BCMA Approval

 
• By Andrew McConaghie
  
SC2007_GSK_1123492961_1200.jpg
GSK is looking to break back into the oncology market

More from Anticancer

More from Therapy Areas